Skip to main content
NCBI home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 1998 Jan;64(1):50–55. doi: 10.1136/jnnp.64.1.50

Exploratory treatment trials in multiple sclerosis using MRI: sample size calculations for relapsing-remitting and secondary progressive subgroups using placebo controlled parallel groups

N Tubridy 1, H Ader 1, F Barkhof 1, A Thompson 1, D Miller 1
PMCID: PMC2169905  PMID: 9436727

Abstract

OBJECTIVES—Serial brain MRI is widely used in pilot studies of new agents to monitor treatment efficacy in relapsing-remitting (RR) and secondary progressive (SP) multiple sclerosis (MS). For pilot trials, sample size calculations for the RR subgroup are based on the data from small numbers of patients and separate calculations for the SP subgroup have not been performed. The present study considers these issues.
METHODS—The sample size calculations were based on data from six months of monthly T2 weighted and gadolinium enhanced MRI in 31 RR and 28 SP untreated patients undergoing natural history studies or in the placebo arm of a therapeutic trial. The calculations were for a placebo controlled, parallel groups design lasting six months. The sample sizes were based on bootstrap analysis with an 80% likelihood of showing a given treatment effect.
RESULTS—With a single pretreatment scan, demonstration of a 70% reduction in newly active lesions required 2×30 RR and 2×50 SP patients. With an extra run-in scan one month before treatment, the sample sizes were 2×20 for RR and 2×30 for SP patients.
CONCLUSIONS—The sample sizes required for RR patients were comparable with previous smaller studies. Larger sample sizes were needed for the SP group, but the extra run in scan resulted in a reduction in both groups. The larger sample sizes in the SPMS group were probably due to the combination of a higher proportion of patients with low MRI activity (⩽2 active MRI lesions in 50% of SP and 32% RR patients), as well as a few patients who displayed extremely high activity, thus increasing interpatient variability. These data should be considered in planning pilot MRI outcome trials.



Full Text

The Full Text of this article is available as a PDF (124.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barkhof F., Tas M. W., Frequin S. T., Scheltens P., Hommes O. R., Nauta J. J., Valk J. Limited duration of the effect of methylprednisolone on changes on MRI in multiple sclerosis. Neuroradiology. 1994 Jul;36(5):382–387. doi: 10.1007/BF00612124. [DOI] [PubMed] [Google Scholar]
  2. Confavreux C., Aimard G., Devic M. Course and prognosis of multiple sclerosis assessed by the computerized data processing of 349 patients. Brain. 1980 Jun;103(2):281–300. doi: 10.1093/brain/103.2.281. [DOI] [PubMed] [Google Scholar]
  3. Edan G., Miller D., Clanet M., Confavreux C., Lyon-Caen O., Lubetzki C., Brochet B., Berry I., Rolland Y., Froment J. C. Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria. J Neurol Neurosurg Psychiatry. 1997 Feb;62(2):112–118. doi: 10.1136/jnnp.62.2.112. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Efron B., Tibshirani R. Statistical data analysis in the computer age. Science. 1991 Jul 26;253(5018):390–395. doi: 10.1126/science.253.5018.390. [DOI] [PubMed] [Google Scholar]
  5. Grossman R. I., Braffman B. H., Brorson J. R., Goldberg H. I., Silberberg D. H., Gonzalez-Scarano F. Multiple sclerosis: serial study of gadolinium-enhanced MR imaging. Radiology. 1988 Oct;169(1):117–122. doi: 10.1148/radiology.169.1.3420246. [DOI] [PubMed] [Google Scholar]
  6. Isaac C., Li D. K., Genton M., Jardine C., Grochowski E., Palmer M., Kastrukoff L. F., Oger J., Paty D. W. Multiple sclerosis: a serial study using MRI in relapsing patients. Neurology. 1988 Oct;38(10):1511–1515. doi: 10.1212/wnl.38.10.1511. [DOI] [PubMed] [Google Scholar]
  7. Karussis D. M., Meiner Z., Lehmann D., Gomori J. M., Schwarz A., Linde A., Abramsky O. Treatment of secondary progressive multiple sclerosis with the immunomodulator linomide: a double-blind, placebo-controlled pilot study with monthly magnetic resonance imaging evaluation. Neurology. 1996 Aug;47(2):341–346. doi: 10.1212/wnl.47.2.341. [DOI] [PubMed] [Google Scholar]
  8. Kermode A. G., Thompson A. J., Tofts P., MacManus D. G., Kendall B. E., Kingsley D. P., Moseley I. F., Rudge P., McDonald W. I. Breakdown of the blood-brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis. Pathogenetic and clinical implications. Brain. 1990 Oct;113(Pt 5):1477–1489. doi: 10.1093/brain/113.5.1477. [DOI] [PubMed] [Google Scholar]
  9. Kidd D., Thorpe J. W., Kendall B. E., Barker G. J., Miller D. H., McDonald W. I., Thompson A. J. MRI dynamics of brain and spinal cord in progressive multiple sclerosis. J Neurol Neurosurg Psychiatry. 1996 Jan;60(1):15–19. doi: 10.1136/jnnp.60.1.15. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Lublin F. D., Reingold S. C. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology. 1996 Apr;46(4):907–911. doi: 10.1212/wnl.46.4.907. [DOI] [PubMed] [Google Scholar]
  11. McFarland H. F., Frank J. A., Albert P. S., Smith M. E., Martin R., Harris J. O., Patronas N., Maloni H., McFarlin D. E. Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis. Ann Neurol. 1992 Dec;32(6):758–766. doi: 10.1002/ana.410320609. [DOI] [PubMed] [Google Scholar]
  12. Miller D. H., Albert P. S., Barkhof F., Francis G., Frank J. A., Hodgkinson S., Lublin F. D., Paty D. W., Reingold S. C., Simon J. Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis. US National MS Society Task Force. Ann Neurol. 1996 Jan;39(1):6–16. doi: 10.1002/ana.410390104. [DOI] [PubMed] [Google Scholar]
  13. Miller D. H., Thompson A. J., Morrissey S. P., MacManus D. G., Moore S. G., Kendall B. E., Moseley I. F., McDonald W. I. High dose steroids in acute relapses of multiple sclerosis: MRI evidence for a possible mechanism of therapeutic effect. J Neurol Neurosurg Psychiatry. 1992 Jun;55(6):450–453. doi: 10.1136/jnnp.55.6.450. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Nauta J. J., Thompson A. J., Barkhof F., Miller D. H. Magnetic resonance imaging in monitoring the treatment of multiple sclerosis patients: statistical power of parallel-groups and crossover designs. J Neurol Sci. 1994 Mar;122(1):6–14. doi: 10.1016/0022-510x(94)90045-0. [DOI] [PubMed] [Google Scholar]
  15. Noseworthy J. H., Vandervoort M. K., Wong C. J., Ebers G. C. Interrater variability with the Expanded Disability Status Scale (EDSS) and Functional Systems (FS) in a multiple sclerosis clinical trial. The Canadian Cooperation MS Study Group. Neurology. 1990 Jun;40(6):971–975. doi: 10.1212/wnl.40.6.971. [DOI] [PubMed] [Google Scholar]
  16. Poser C. M., Paty D. W., Scheinberg L., McDonald W. I., Davis F. A., Ebers G. C., Johnson K. P., Sibley W. A., Silberberg D. H., Tourtellotte W. W. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol. 1983 Mar;13(3):227–231. doi: 10.1002/ana.410130302. [DOI] [PubMed] [Google Scholar]
  17. Rudick R., Antel J., Confavreux C., Cutter G., Ellison G., Fischer J., Lublin F., Miller A., Petkau J., Rao S. Clinical outcomes assessment in multiple sclerosis. Ann Neurol. 1996 Sep;40(3):469–479. doi: 10.1002/ana.410400321. [DOI] [PubMed] [Google Scholar]
  18. Runmarker B., Andersen O. Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up. Brain. 1993 Feb;116(Pt 1):117–134. doi: 10.1093/brain/116.1.117. [DOI] [PubMed] [Google Scholar]
  19. Smith M. E., Stone L. A., Albert P. S., Frank J. A., Martin R., Armstrong M., Maloni H., McFarlin D. E., McFarland H. F. Clinical worsening in multiple sclerosis is associated with increased frequency and area of gadopentetate dimeglumine-enhancing magnetic resonance imaging lesions. Ann Neurol. 1993 May;33(5):480–489. doi: 10.1002/ana.410330511. [DOI] [PubMed] [Google Scholar]
  20. Stone L. A., Smith M. E., Albert P. S., Bash C. N., Maloni H., Frank J. A., McFarland H. F. Blood-brain barrier disruption on contrast-enhanced MRI in patients with mild relapsing-remitting multiple sclerosis: relationship to course, gender, and age. Neurology. 1995 Jun;45(6):1122–1126. doi: 10.1212/wnl.45.6.1122. [DOI] [PubMed] [Google Scholar]
  21. Thompson A. J., Kermode A. G., Wicks D., MacManus D. G., Kendall B. E., Kingsley D. P., McDonald W. I. Major differences in the dynamics of primary and secondary progressive multiple sclerosis. Ann Neurol. 1991 Jan;29(1):53–62. doi: 10.1002/ana.410290111. [DOI] [PubMed] [Google Scholar]
  22. Thompson A. J., Miller D., Youl B., MacManus D., Moore S., Kingsley D., Kendall B., Feinstein A., McDonald W. I. Serial gadolinium-enhanced MRI in relapsing/remitting multiple sclerosis of varying disease duration. Neurology. 1992 Jan;42(1):60–63. doi: 10.1212/wnl.42.1.60. [DOI] [PubMed] [Google Scholar]
  23. Thorpe J. W., Kidd D., Moseley I. F., Kenndall B. E., Thompson A. J., MacManus D. G., McDonald W. I., Miller D. H. Serial gadolinium-enhanced MRI of the brain and spinal cord in early relapsing-remitting multiple sclerosis. Neurology. 1996 Feb;46(2):373–378. doi: 10.1212/wnl.46.2.373. [DOI] [PubMed] [Google Scholar]
  24. Whitaker J. N., McFarland H. F., Rudge P., Reingold S. C. Outcomes assessment in multiple sclerosis clinical trials: a critical analysis. Mult Scler. 1995 Apr;1(1):37–47. doi: 10.1177/135245859500100107. [DOI] [PubMed] [Google Scholar]
  25. Willoughby E. W., Grochowski E., Li D. K., Oger J., Kastrukoff L. F., Paty D. W. Serial magnetic resonance scanning in multiple sclerosis: a second prospective study in relapsing patients. Ann Neurol. 1989 Jan;25(1):43–49. doi: 10.1002/ana.410250107. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES